Atara Biotherapeutics Inc (AT2.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
As of 09:10AM CEST. Market open.
| Previous close | 0.36 |
| Open | 0.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.36 - 9.09 |
| 52-week range | 0.36 - 56.28 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
- Zacks
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
- Simply Wall St.
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
Atara Biotherapeutics ( NASDAQ:ATRA ) First Quarter 2024 Results Key Financial Results Revenue: US$27.4m (up by...
© 2024 Yahoo. All rights reserved.